# EDGAR Filing Document

**Accession Number:** 0001638287
**File Stem:** 0001104659-26-071358
**Filing Date:** 2026-6
**Character Count:** 13095
**Document Hash:** 71c8492777e7ee86861489a4445bf53e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-071358.hdr.sgml**: 20260608

**ACCESSION NUMBER**: 0001104659-26-071358

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260608

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260608

**DATE AS OF CHANGE**: 20260608

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MetaVia Inc.
- **CENTRAL INDEX KEY:** 0001638287
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 472389984
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37809
- **FILM NUMBER:** 261072494

**BUSINESS ADDRESS:**
- **STREET 1:** 545 CONCORD AVENUE
- **STREET 2:** SUITE 210
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02138
- **BUSINESS PHONE:** (857) 702-9600

**MAIL ADDRESS:**
- **STREET 1:** 545 CONCORD AVENUE
- **STREET 2:** SUITE 210
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02138

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NeuroBo Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20191231

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Gemphire Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20150331

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 8, 2026**

![](tm2615356d2_8kimg001.jpg)

**METAVIA INC.**

**(Exact name of Registrant as Specified in Its Charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37809** | **47-2389984** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |
| **545 Concord Avenue** **, Suite 210**<br> **Cambridge** **, Massachusetts**<br> (Address of principal executive offices) |  | **02138**<br> (Zip Code) |

---

**(857) 702-9600**

(Registrant's telephone number, including area code)

**Not applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br> Symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, par value $0.001 per share** | **MTVA** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |

---

On June 8, 2026, at the 2026 virtual annual meeting of stockholders (the ***"Annual Meeting"***) of MetaVia Inc. (the ***"Company"***), the stockholders of the Company approved the first amendment (the ***"First Amendment"***) to the MetaVia Inc. 2022 Amended and Restated Equity Incentive Plan, as amended on November 29, 2024 (the ***"2022 Equity Incentive Plan"***), which was previously approved by the Board of Directors of the Company. The First Amendment became effective upon stockholder approval, and provides for an increase in the aggregate number of shares of the Company's common stock, par value $0.001 per share (the ***"Common Stock"***), that may be issued pursuant to the 2022 Equity Incentive Plan by 200,000 shares.

Except as amended by the First Amendment, the other terms of the 2022 Equity Incentive Plan remain in full force and effect. A description of the terms of the First Amendment and 2022 Equity Incentive Plan is included in "Proposal 4 Approval of the First Amendment to Our 2022 Equity Incentive Plan" in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 27, 2026 (the ***"Proxy Statement"***), which description is incorporated herein by reference. Such description is a summary only and is qualified in its entirety by reference to the full text of the First Amendment and 2022 Equity Incentive Plan included in such definitive proxy statement. The First Amendment is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders.** |

---

On June 8, 2026, the Company held its Annual Meeting, whereby the Company's stockholders voted on five proposals at the Annual Meeting as set forth below, each of which is described in more detail in the Proxy Statement. There were 2,866,545 shares of Common Stock present and entitled to vote at the Annual Meeting, online or by proxy, which constituted a quorum for the transaction of business. In deciding the proposals at the Annual Meeting, each share of Common Stock represented one vote.

At the Annual Meeting, the Company's stockholders voted on the following proposals:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. To elect two Class I directors, each to serve a three-year term until the 2029 annual meeting
 of stockholders and until the election and qualification of such director's successor, or such director's earlier death,
 resignation, or removal (the  ***"Class I Directors Proposal"***);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. To ratify the appointment of BDO USA, P.C.
 as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. To approve an amendment to the Company's
 Third Amended and Restated Certificate of Incorporation, as amended, to effect a reverse split of the Company's outstanding
 Common Stock at a ratio in the range of 1-for-5 to 1-for-22 to be determined at the discretion of the Company's Board
 of Directors, whereby each outstanding 5 to 22 shares of Common Stock would be combined, converted and changed into one share of the
 Company's Common Stock (the  ***"Reverse Stock Split Proposal"***);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. To approve the First Amendment to the 2022 Equity Incentive Plan to increase the aggregate number of
 shares of Common Stock that may be issued pursuant to awards by 200,000 shares of Common Stock (the  ***"Equity Plan Proposal"***);
 and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. To authorize one or more adjournments of the
 Annual Meeting to solicit additional proxies in the event there are insufficient votes to approve Proposals 3 and 4 described above
 (the  ***"Adjournment Proposal"***).

The voting results at the Annual Meeting are shown below:

***Proposal 1—The Class I Directors Proposal.***

---

| | | | |
|:---|:---|:---|:---|
| **Class I Nominees** | **Votes For** | **Votes Withheld** | **Broker Non-Votes** |
| D. Gordon Strickland | 1927368 | 7372 | 931805 |
| James P. Tursi, M.D. | 1926735 | 8005 | 931805 |

---

D. Gordon Strickland and James P. Tursi, M.D. were elected as Class I directors to serve until the 2029 annual meeting of stockholders.

 ****

***Proposal 2—Ratification of the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.***

---

| | | |
|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** |
| 2772109 | 89718 | 4718 |

---

The stockholders ratified the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. There were no broker non-votes on this matter.

 ****

***Proposal 3—***  ***The Reverse Stock Split Proposal.***

---

| | | |
|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** |
| 2472949 | 373239 | 20357 |

---

 ****

The stockholders approved the Reverse Stock Split Proposal. There were no broker non-votes on this matter.

 ****

***Proposal 4—The Equity Plan Proposal.***

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 1893233 | 35799 | 5708 | 931805 |

---

 ****

The stockholders approved the Equity Plan Proposal.

***Proposal 5—The Adjournment Proposal.***

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 1902616 | 29372 | 2752 | 931805 |

---

The stockholders approved the Adjournment Proposal.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.** |

---

**(d) Exhibits**

---

| | |
|:---|:---|
| Exhibit<br> Number | Exhibit Description |
| [10.1](tm2615356d2_ex10-1.htm) | [First Amendment to the MetaVia Inc. Amended and Restated 2022 Equity Incentive Plan.](tm2615356d2_ex10-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **METAVIA INC.** | **METAVIA INC.** |
| Date: June 8, 2026 | By: | */s/ Hyung Heon Kim* |
|  |  | Hyung Heon Kim |
|  |  | President and Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**FIRST AMENDMENT TO THE<br> METAVIA INC. AMENDED AND RESTATED 2022 EQUITY INCENTIVE PLAN**

**RECITALS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. The MetaVia Inc. Amended and Restated 2022 Equity Incentive Plan (the  ***"Plan"***),
initially adopted by our Board on November 8, 2022, approved by our stockholders on December 22, 2022, and further amended by the Board
on November 29, 2024, is hereby amended by this First Amendment to the Plan (this  ***"First Amendment"***) as set
forth below. This First Amendment shall be effective from and after the date that this First Amendment is approved by the stockholders
of the Company in accordance with the terms of the Plan. Following such effective date, any reference to the "Plan" shall
mean the Plan, as amended by this First Amendment. All capitalized terms used but not otherwise defined herein shall have the respective
meanings ascribed to such terms in the Plan.

**AMENDMENT**

&nbsp;&nbsp;&nbsp;&nbsp;1. Section 2(a) of the Plan is hereby deleted in its entirety and replaced with the following:

"**(a) Share Reserve.** Subject to adjustment in accordance with <u>Section 2(c)</u> and any adjustments as necessary to implement any Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed the sum of (i) 506,201 shares, plus (ii) the Prior Plan's Available Reserve, plus (iii) the number of Returning Shares, if any, as such shares become available from time to time. In addition, subject to any adjustments as necessary to implement any Capitalization Adjustments, such aggregate number of shares of Common Stock will automatically increase on January 1st of each year for a period of eight years commencing on January 1, 2025 and ending on (and including) January 1, 2032, to an amount equal to 10% of the Fully Diluted Shares as of the last day of the preceding calendar year; provided, however that the Board may act prior to the effective date of any such annual increase to provide that the increase for such year will be a lesser number of shares of Common Stock."

&nbsp;&nbsp;&nbsp;&nbsp;2. Except as set forth in this First Amendment, the Plan shall be unaffected hereby and shall remain in full
force and effect.